19868
document
A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism . Repetitive behaviors are a core symptom domain in autism that has been linked to alterations in the serotonin system . While the selective serotonin-receptive inhibitor fluvoxamine has been shown to be effective in adults with autism , as yet no published placebo controlled trials with these agents document safety and efficacy in children with autism . This study examines the selective serotonin reuptake inhibitor liquid fluoxetine in the treatment of repetitive behaviors in childhood and adolescent autism spectrum disorders ( ASDs ) . In total , 45 child or adolescent patients with ASD were randomized into two acute 8-week phases in a double-blind placebo-controlled crossover study of liquid fluoxetine . Study design included two randomized 8-week fluoxetine and placebo phases separated by a 4-week washout phase . Outcome measures included measures of repetitive behaviors and global improvement . Low-dose liquid fluoxetine ( mean final dose : 9.9+/-4.35 mg/day ) was superior to placebo in the treatment of repetitive behaviors by CY-BOCS compulsion scale . The effect size was in the moderate to large range , and the doses used were low . Liquid fluoxetine was only slightly , and not significantly , superior to placebo on CGI autism score partially due to a phase order effect . However , fluoxetine was marginally superior to placebo on a composite measure of global effectiveness . Liquid fluoxetine did not significantly differ from placebo on treatment emergent side effects . Liquid fluoxetine in low doses is more effective than placebo in the treatment of repetitive behaviors in childhood autism . Limitations include small sample size and the crossover design of the study . Further replication and long-term maintenance trials are needed .
19869
Intervention_Pharmacological
serotonin-receptive inhibitor fluvoxamine
19870
Intervention_Control
placebo
19871
Intervention_Pharmacological
serotonin reuptake inhibitor liquid fluoxetine
19872
Intervention_Pharmacological
liquid fluoxetine
19873
Intervention_Pharmacological
fluoxetine
19874
Intervention_Pharmacological
liquid fluoxetine
19875
Intervention_Control
placebo
19876
Intervention_Pharmacological
Liquid fluoxetine
19877
Intervention_Pharmacological
fluoxetine
19878
Intervention_Pharmacological
Liquid fluoxetine
19879
Outcome_Mental
repetitive behaviors
19880
Outcome_Mental
Repetitive behaviors
19881
Outcome_Other
safety
19882
Outcome_Other
efficacy
19883
Outcome_Mental
repetitive behaviors
19884
Outcome_Mental
measures of repetitive behaviors
19885
Outcome_Mental
global improvement
19886
Outcome_Mental
repetitive behaviors
19887
Outcome_Mental
CY-BOCS compulsion scale
19888
Outcome_Other
effect size
19889
Outcome_Mental
CGI autism score
19890
Outcome_Mental
composite measure of global effectiveness
19891
Outcome_Adverse-effects
treatment emergent side effects
19892
Outcome_Mental
repetitive behaviors
19893
Participant_Age
childhood and adolescent
19894
Participant_Condition
autism
19895
Participant_Condition
autism spectrum disorders
19896
Participant_Condition
ASDs
19897
Participant_Sample-size
45
19898
Participant_Age
child or adolescent
19899
Participant_Condition
ASD